Approval of Aduhelm was a landmark event for the Alzheimer’s field and, most importantly, provided hope for the millions of people living with early Alzheimer’s, and their families. It was the first FDA-approved treatment to address one of the underlying causes of the disease, not just the symptoms. And the field has continued to advance. 
 

• Leqembi is FDA-approved and available now, and is covered by Medicare when the prescribing physician participates in a CMS-approved registry.
• Donanemab is in review at the FDA; a decision is expected in the coming months.
• The Alzheimer’s treatment pipeline is robust, with a wide variety of treatment targets being investigated.

The Alzheimer’s Association recommends that people receiving Aduhelm through a clinical trial or by prescription, and their families, should connect with their study contact and/or their personal health care provider to talk through how these changes will impact their treatment and care.

CMS denied Medicare coverage to this treatment — approved by the FDA using the accelerated approval pathway — unless the patient was enrolled in a clinical trial. We believe this contributed to limiting the number of people living with Alzheimer’s, a fatal disease, who could get access to the approved treatment, and created significant confusion for patients and doctors.

More information about Alzheimer’s diagnosis, treatment and coverage options, and dozens of Alzheimer’s/dementia research studies near you, is available at the Alzheimer’s Association website at alz.org.
 

About the Alzheimer’s Association

The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia®. Visit alz.org or call 800.272.3900.